UBS Downgrades Mylan Labs to 'Neutral'

Analyst Steven Valiquette now sees lower sales for drugmaker's generic pain treatment

UBS Financial downgraded Mylan Labs (MYL ) to neutral from buy.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.